Komipharm International Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

5.70

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

—

Rev. gr., 5y

-0.51%

Revenues

42.65b

+7.15%

Net income

-3.98b

L-38.91%

CFO

-2.80b

L+54.88%

Earnings

Feb 19, 2025

URL

IPO date

Oct 30, 2001

Employees

Domiciled in

Incorporated in

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues	42,647,035 7.15%	39,800,518 11.03%
Cost of revenue	40,608,972	35,171,750
Unusual Expense (Income)
NOPBT	2,038,063	4,628,768
NOPBT Margin	4.78%	11.63%
Operating Taxes	171,152	(3,157,984)
Tax Rate	8.40%
NOPAT	1,866,911	7,786,752
Net income	(3,979,103) -38.91%	(6,513,790) 46.07%
Dividends
Dividend yield
Proceeds from repurchase of equity	(62,885)	(999,507)
BB yield	0.02%	0.20%
Debt
Debt current	40,508,115	34,815,879
Long-term debt	5,107,025	3,748,996
Deferred revenue
Other long-term liabilities	1,760,936	10
Net debt	28,176,745	26,537,717
Cash flow
Cash from operating activities	(2,799,882)	(1,807,820)
CAPEX	(636,784)	(1,065,275)
Cash from investing activities	(3,501,939)	(1,375,527)
Cash from financing activities	10,531,211	2,034,236
FCF	6,270,355	8,037,422
Balance
Cash	14,819,530	10,804,591
Long term investments	2,618,864	1,222,567
Excess cash	15,306,043	10,037,132
Stockholders' equity	(13,045,477)	(12,643,367)
Invested Capital	116,245,795	116,421,726
ROIC	1.60%	6.95%
ROCE	1.91%	4.39%
EV
Common stock shares outstanding	69,809	77,093
Price	4,190.00 -34.02%	6,350.57 -18.63%
Market cap	292,498,947 -40.26%	489,584,884 -10.53%
EV	324,353,035	521,138,898
EBITDA	5,567,318	8,454,892
EV/EBITDA	58.26	61.64
Interest	2,551,945	2,216,081
Interest/NOPBT	125.21%	47.88%